BNTX:NASDAQ
BioNTech SE - ADR
95,73 USD
arrow_downward
-1,96%(-1,91) 1D
96,50 USD
arrow_upward
+0,80% (+0,77)bedtimeAfter hours
Closed: 6-окт., 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
99,49 USD
High
100,02 USD
Low
95,31 USD
Mkt. cap
23,87 млд
Avg. vol.
1,04 млн
Volume
0,00
52-wk high
123,98 USD
52-wk low
79,52 USD
EPS
-7,53 USD
Beta
1,22
Shares outstanding
251,20 млн
No. of employees
8 миң
Open
99,49 USD
High
100,02 USD
Low
95,31 USD
Mkt. cap
23,87 млд
Avg. vol.
1,04 млн
Volume
0,00
52-wk high
123,98 USD
52-wk low
79,52 USD
EPS
-7,53 USD
Beta
1,22
Shares outstanding
251,20 млн
No. of employees
8 миң
News stories
From web sources and news partners
Investing.com Nigeria
·
1 саат мурун
Form 4 BioNTech SE For: 7 October By Investing.com
AD HOC NEWS
·
7 саат мурун
BioNTech stock fell 1.96 percent despite a Buy consensus
AD HOC NEWS
·
17 саат мурун
Morgan Stanley sets a Buy rating for BioNTech stock
Yahoo Finance
·
1 күн мурун
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR